IGM Biosciences, Inc. (IGMS)
US — Healthcare Sector
Automate Your Wheel Strategy on IGMS
With Tiblio's Option Bot, you can configure your own wheel strategy including IGMS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol IGMS
- Rev/Share 0.0438
- Book/Share 0.0114
- PB 102.5221
- Debt/Equity 62.9814
- CurrentRatio 5.7111
- ROIC -1.1281
- MktCap 70334639.0
- FreeCF/Share -2.3952
- PFCF -0.4801
- PE -0.3598
- Debt/Assets 0.2125
- DivYield 0
- ROE -3.1797
- Rating D+
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | IGMS | RBC Capital Mkts | Outperform | Sector Perform | $20 | $1.5 | Jan. 10, 2025 |
| Downgrade | IGMS | BMO Capital Markets | Outperform | Market Perform | $21 | $2 | Jan. 10, 2025 |
| Downgrade | IGMS | Guggenheim | Buy | Neutral | -- | -- | Jan. 10, 2025 |
| Downgrade | IGMS | Stifel | Buy | Hold | $27 | $2.5 | Jan. 10, 2025 |
| Downgrade | IGMS | Morgan Stanley | Equal Weight | Underweight | $12 | $2 | Jan. 10, 2025 |
| Initiation | IGMS | BMO Capital Markets | -- | Outperform | -- | $21 | Dec. 6, 2024 |
| Downgrade | IGMS | JP Morgan | Neutral | Underweight | $12 | $9 | Oct. 1, 2024 |
| Downgrade | IGMS | Truist | Buy | Hold | $24 | $12 | Oct. 1, 2024 |
News
About IGM Biosciences, Inc. (IGMS)
- IPO Date 2019-09-18
- Website https://igmbio.com
- Industry Biotechnology
- CEO Ms. Mary Beth Harler M.D.
- Employees 149
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia. It has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.